Antihypertensive drugs in pregnancy
- PMID: 2865023
Antihypertensive drugs in pregnancy
Abstract
When mean arterial pressure exceeds 140 mmHg (equivalent to 180/120), there is a significant risk of maternal cerebral vascular damage. Therefore it is recommended that blood pressures greater than 170/110 should be treated with urgency, aiming to maintain the blood pressure at all times at less than 170/110 but not lower than 130/90. Parenteral hydralazine is effective and safe therapy. Labetalol (intravenously or orally) appears to be as effective and as safe, and causes fewer troublesome side effects; however, clinical experience of its use is more limited, particularly in relation to its safety for the fetus and neonate. Delivery of the fetus is usually the definitive management of severe hypertension in pregnancy. However, this action may not reduce the blood pressure immediately. After initial treatment with rapid-acting agents, it is often advantageous to maintain control of arterial pressure with ongoing oral therapy (methyldopa, labetalol). In addition to the protective effect on the mother, such therapy may allow delivery of the fetus to be deferred; this should be considered only if the fetus is significantly premature (e.g., less than 34 weeks), there is no other evidence of maternal or fetal distress, and there can be meticulous monitoring of the maternal and fetal state proceeding to prompt delivery if deterioration occurs. The indications for treatment of mild or moderate hypertension in pregnancy are less clear. Severe hypertensive episodes can be reduced by several drugs (methyldopa, labetalol, beta-blockers). Methyldopa appears to reduce the small risk of mid-trimester abortions seen in association with early hypertension. Other benefits may be possible with other individual drugs; however, none of these have been found consistently in controlled studies to date. There seems, therefore, to be no definite indication for treatment of mild hypertension in pregnancy; treatment of moderate hypertension may be reasonable but its value is unproved at present. Antihypertensive drugs are valuable in pregnancy to reduce the risks directly due to elevated blood pressure. These drugs are not expected to affect the evolution of preeclampsia nor to treat the other complications of this condition.
Similar articles
-
Management of the pregnant patient with chronic hypertension.Clin Ther. 1983;5(6):568-78. Clin Ther. 1983. PMID: 6138151 Review.
-
Treatment of hypertension in pregnancy.Clin Obstet Gynaecol. 1986 Jun;13(2):307-17. Clin Obstet Gynaecol. 1986. PMID: 2873916 Review.
-
[Treatment of hypertensive diseases in pregnancy--general recommendations and long-term oral therapy].Z Geburtshilfe Neonatol. 1997 Nov-Dec;201(6):240-6. Z Geburtshilfe Neonatol. 1997. PMID: 9491543 Review. German.
-
The control of hypertension in pregnancy.Obstet Gynecol Annu. 1981;10:69-106. Obstet Gynecol Annu. 1981. PMID: 6116219 Review. No abstract available.
-
The use of antihypertensive drugs in hypertension in pregnancy.Clin Obstet Gynaecol. 1977 Dec;4(3):685-705. Clin Obstet Gynaecol. 1977. PMID: 23234 Review. No abstract available.
Cited by
-
Hypertension in pregnancy: whom and how to treat.Br J Clin Pharmacol. 1987;24 Suppl 1(Suppl 1):15S-20S. doi: 10.1111/j.1365-2125.1987.tb03263.x. Br J Clin Pharmacol. 1987. PMID: 3326631 Free PMC article. Review.
-
Severe pre-eclampsia and infants of very low birth weight.Arch Dis Child. 1987 Jul;62(7):712-6. doi: 10.1136/adc.62.7.712. Arch Dis Child. 1987. PMID: 3632019 Free PMC article.
-
Hypertension in pregnancy.J Natl Med Assoc. 1994 Apr;86(4):289-93. J Natl Med Assoc. 1994. PMID: 8040904 Free PMC article. Review.
-
Independent Determinants of Maternal and Fetal Outcomes in a Sample of Pregnant Outpatients With Normal Blood Pressure, Chronic Hypertension, Gestational Hypertension, and Preeclampsia.J Clin Hypertens (Greenwich). 2015 Oct;17(10):777-82. doi: 10.1111/jch.12614. Epub 2015 Jul 14. J Clin Hypertens (Greenwich). 2015. PMID: 26173048 Free PMC article.
-
Neonatal inflammatory submandibular sialadenitis associated with prenatal methyldopa exposure.J Pediatr Pharmacol Ther. 2014 Apr;19(2):132-4. doi: 10.5863/1551-6776-19.2.132. J Pediatr Pharmacol Ther. 2014. PMID: 25024674 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical